All In Biotech

Drug Trial Radar · NCT07743931

Study on the Management of COMISA

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Sep 30, 2026

Primary completion

Sep 2028

Study completion Sep 2029

Sponsor

Lead sponsor
University Hospital, GrenobleAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Polyclinique Saint-Laurent - Hospitalité Saint-Thomas de Villeneuve; Hôpital Européen Marseille; Centre Médical les Jasmins "Poumon et Sommeil"; Hôpital de la Pitié Salpêtrière - AP-HP
First posted
Aug 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

COMISA, the combination of obstructive sleep apnea (OSA) and insomnia, is a frequent and burdensome condition. Many patients with OSA experience clinically significant insomnia symptoms, and a substantial proportion of individuals with chronic insomnia also meet criteria for OSA. This comorbidity is associated with more severe symptoms, more complex diagnostic pathways, and reduced adherence to continuous positive airway pressure (CPAP) therapy. This study aims to better understand COMISA and evaluate whether adding daridorexant to CPAP treatment can improve treatment adherence and overall patient outcomes.

Conditions

  • Obstructive Sleep Apnea (OSA)
  • Insomnia
  • COMISA

Interventions

  • Daridorexant 50 mgDrug

    Daridorexant initiated for 1 month before CPAP and prescribed as part of routine care.

  • Continuous Positive Air Pressure (CPAP)Device

    PAP therapy initiated after 1 month of Daridorexant, according to standard clinical practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate, in patients diagnosed with COMISA and treated with CPAP, the impact of daridorexant on CPAP adherence at 4 months compared with patients not receiving daridorexant.Time frame: 4 months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • CHU Grenoble Alpes

    Grenoble, France · Recruiting

  • Hôpital Européen Marseille

    Marseille, France · Not yet recruiting

  • Centre Médical Les Jasmins

    Metz, France · Not yet recruiting

  • Hôpital de la Pitié Salpêtrière - AP-HP

    Paris, France · Not yet recruiting

  • Polyclinique Saint-Laurent - Hospitalité Saint-Thomas de Villeneuve

    Rennes, France · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.